Investigating potential pharmacodynamic effects in an early phase of central nervous system
(CNS) drug research can provide valuable information for further development of new …

To systematically study the pharmacodynamics of a CNS drug early in the development
process, we developed and validated a battery of drug-sensitive CNS tests, which we call …

An important objective of early development of drugs for neurobehavioral conditions is to
demonstrate a drug-related central nervous system (CNS) effect. For this, functional …

Background Loss of cholinergic signaling is principally related to cognitive decline in
Alzheimer's Disease (AD), and stimulation of these receptors improves cognitive …

Objectives Cognitive impairment models are used in clinical studies aimed at proving
pharmacology of drugs being developed for Alzheimer's disease and other cognitive …

The go-to cognitive enhancers of today are those that are widely available rather than
optimal for the user, including drugs typically prescribed for treatment of ADHD (eg …

Despite the abundance of cognitive enhancer mechanisms identified in basic research,
drugs approved for cognitive disorders are scarce and of limited efficacy. Although the so …

The role that glia play in neurological disease is poorly understood but increasingly
acknowledged to be critical in a diverse group of disorders. Here we use a simple genetic …

Covering the latest advances in CNS drug development, this book will guide all those
involved in pre-clinical to early clinical trials. The authors describe how recent innovations …

In recent years, the field of psychiatric neuroscience has generated numerous biological
markers that have contributed to our understanding of central nervous system disorders …